Description: DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Home Page: diasoringroup.com/en
Via Crescentino
Saluggia,
VC
13040
Italy
Phone:
39 01 614871
Officers
| Name | Title |
|---|---|
| Mr. Carlo Rosa | CEO, GM & Executive Director |
| Dr. Chen Menachem Even | Chief Commercial Officer, Senior Corporate VP of Commercial Operations & Executive Director |
| Mr. Piergiorgio Pedron | Senior Corporate VP, CFO & Corporate Accounting Documents Officer |
| Mr. Fabrizio Piercarlo Bonelli | Corporate VP & Chief Technology Officer |
| Dr. Riccardo Fava | Corporate Vice President of Communication, ESG & Investor Relations |
| Mr. Ulisse Spada | Corporate VP, Head of the Legal Department, Secretary & General Counsel |
| Ms. Amelia Parente | Senior Corporate Vice President of Human Resources |
| Mr. Angelo Rago | President of Luminex Corporation |
Exchange: MI
Country: IT : Italy
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 22.4215 |
|---|---|
| Trailing PE: | 31.393 |
| Price-to-Book MRQ: | 3.4114 |
| Price-to-Sales TTM: | 4.7401 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3184 |